Movano Health to launch Evie Ring Nov 20; reports Q3 net loss $9.0M

Corvex, Inc.

Evie Ring launches Nov 20 at $269 with no subscription; shipping expected by year-end.
Blood pressure SoC met FDA accuracy standards in clinical study; pivotal trial planned.
FDA requested additional info on Evie Ring pulse oximeter 510(k); reply planned Q1 2024.
Priced $3.6M public offering of 4.2M shares at $0.85; expected close Nov 17.
Q3 net loss $9.0M ($0.18 loss per share); no revenue; pro forma cash $10.8M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Corvex, Inc. reported the three months ending September 30, 2023 results: net income $9.0 million, EPS $(0.18) per basic and diluted share.

Period: the three months ending September 30, 2023
Net income: $9.0 million
EPS: $(0.18) per basic and diluted share
Result: reported results

Exact text from the filing

Movano Health reported a net loss of $9.0 million and a loss of $(0.18) per basic and diluted share, in the third quarter of 2023

View on SEC.gov

Browse all earnings releases →

Corvex, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-087243

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.